Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles
暂无分享,去创建一个
Colette McDonagh | Andrew M. Davidoff | David E. Williams | Raymond L. Stallings | Vladimir Gubala | R. Stallings | A. Davidoff | V. Gubala | R. Nooney | C. McDonagh | A. Tivnan | H. Lode | Isabella M. Bray | C. Ng | I. Bray | Robert Nooney | Suzanne Prenter | Olga Piskareva | Harry Harvey | Amanda Tivnan | Wayne Shannon Orr | Raquel Domingo-Fernández | Catherine Y. Ng | Holger N. Lode | H. Harvey | O. Piskareva | W. Orr | Suzanne Prenter | R. Domingo-Fernández | C. Ng
[1] Ying Feng,et al. Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .
[2] F. Slack,et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[4] L. Sorkin,et al. Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma--a report of a series. , 1997, Anesthesia and analgesia.
[5] Huiqing Liu,et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma , 2010, BMC Systems Biology.
[6] Sharon J. Diskin,et al. A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.
[7] Kai-Fai Lee,et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. , 2010, Carcinogenesis.
[8] M. Danks,et al. New therapeutic targets for the treatment of high‐risk neuroblastoma , 2009, Journal of cellular biochemistry.
[9] Rogier Versteeg,et al. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2 , 2002, Oncogene.
[10] F. Navid,et al. Anti-GD2 antibody therapy for GD2-expressing tumors. , 2010, Current cancer drug targets.
[11] R. Stallings,et al. MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. , 2010, Cancer research.
[12] B. Calabretta,et al. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. , 2000, Journal of the National Cancer Institute.
[13] David E. Williams,et al. A comparison of mono and multivalent linkers and their effect on the colloidal stability of nanoparticle and immunoassays performance. , 2010, Talanta.
[14] Renate Kunert,et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. , 2005, Molecular immunology.
[15] S. Gillies,et al. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. , 1997, Journal of the National Cancer Institute.
[16] M. Kavallaris,et al. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells , 1999, Oncogene.
[17] C. Barbé,et al. Silica Particles: A Novel Drug‐Delivery System , 2004 .
[18] M. Schwab,et al. Direct and Coordinate Regulation of ATP-binding Cassette Transporter Genes by Myc Factors Generates Specific Transcription Signatures That Significantly Affect the Chemoresistance Phenotype of Cancer Cells* , 2010, The Journal of Biological Chemistry.
[19] R. Stallings,et al. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.
[20] G. Ritter,et al. Ganglioside antigens expressed by human cancer cells. , 1991, Seminars in cancer biology.
[21] M. Ross,et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[22] D. Chung,et al. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma , 2008, Oncogene.
[23] Raymond L. Stallings,et al. Global MYCN Transcription Factor Binding Analysis in Neuroblastoma Reveals Association with Distinct E-Box Motifs and Regions of DNA Hypermethylation , 2009, PloS one.
[24] Michael J Sailor,et al. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. , 2009, Nature materials.
[25] Feng-ping Huang,et al. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. , 2010, Archives of medical research.
[26] Chih-Hao Chang,et al. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. , 2010, Cancer research.
[27] A. Davidoff,et al. Targeting multiple angiogenic pathways for the treatment of neuroblastoma. , 2010, Journal of pediatric surgery.
[28] Eugene S. Kim,et al. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma , 2011, Angiogenesis.
[29] Lin He,et al. MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature reviews genetics.
[30] J Khan,et al. The MYCN oncogene is a direct target of miR-34a , 2008, Oncogene.
[31] B. MacCraith,et al. Experimental and theoretical studies of the optimisation of fluorescence from near-infrared dye-doped silica nanoparticles , 2009, Analytical and bioanalytical chemistry.
[32] W. Saxinger,et al. An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo , 2011, Peptides.
[33] Andrea L Kasinski,et al. MicroRNA therapeutics in preclinical cancer models. , 2011, The Lancet. Oncology.
[34] K. Finnie,et al. Biodegradability of sol–gel silica microparticles for drug delivery , 2009 .
[35] C. Landen,et al. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. , 2005, Cancer research.
[36] D. Higgins,et al. Widespread Dysregulation of MiRNAs by MYCN Amplification and Chromosomal Imbalances in Neuroblastoma: Association of miRNA Expression with Survival , 2009, PloS one.
[37] B. Calabretta,et al. Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. , 2000, Journal of the National Cancer Institute.
[38] K. Morik,et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles , 2010, International journal of cancer.
[39] P. Wingfield,et al. TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.
[40] F. Slack,et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.
[41] Shoko Yoshida,et al. Mechanisms for the Apoptosis of Small Cell Lung Cancer Cells Induced by Anti-GD2 Monoclonal Antibodies , 2005, Journal of Biological Chemistry.
[42] Mark B. Carter,et al. Erratum: The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers (Nature Materials (2011) 10 (389-397)) , 2011 .
[43] S. Gillies,et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. , 1990, Journal of immunology.
[44] M. Cilli,et al. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[45] Anna Katharina Dehof,et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. , 2005, Molecular immunology.
[46] N. Cheung,et al. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] Kathryn A. O’Donnell,et al. Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.
[48] F. Westermann,et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors , 2010, Oncogene.
[49] Yi Tie,et al. Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest , 2008, FEBS letters.
[50] R. Stallings,et al. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. , 2007, Cancer research.
[51] A. Donfrancesco,et al. Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM , 2008, PloS one.
[52] R. Stallings,et al. Therapeutic targeting of miRNAs in neuroblastoma , 2010, Expert opinion on therapeutic targets.
[53] Kim Vn,et al. Small RNAs: classification, biogenesis, and function. , 2005, Molecules and cells.
[54] M. Schrappe,et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. , 1995, European journal of cancer.
[55] M. Yamakuchi,et al. miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.
[56] R. Stallings,et al. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. , 2009, Current pharmaceutical design.
[57] Jayanth Panyam,et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.
[58] F. Tamanoi,et al. Silica nanoparticles as a delivery system for nucleic acid-based reagents. , 2009, Journal of materials chemistry.
[59] B. Liu,et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[60] M. O'sullivan,et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2 , 2010, Molecular Cancer.
[61] M. Uttenreuther-Fischer,et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] R. Stallings,et al. MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. , 2011, Cancer letters.
[63] K. Kelnar,et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.
[64] K. Kelnar,et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.
[65] K. Foon,et al. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2 , 2000, Cancer Gene Therapy.
[66] R. Stallings,et al. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma , 2011, BMC Cancer.
[67] P. Couvreur,et al. Ampicillin-loaded liposomes and nanoparticles: comparison of drug loading, drug release and in vitro antimicrobial activity. , 1991, Journal of microencapsulation.
[68] Scott L Pomeroy,et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. , 2011, Neuro-oncology.
[69] R. Stallings,et al. Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q− Neuroblastoma , 2010, Clinical Cancer Research.
[70] V. Kim,et al. Small RNAs: classification, biogenesis, and function. , 2005, Molecules and cells.
[71] So-Jung Park,et al. Size-dependent shape evolution of silica nanoparticles into hollow structures. , 2008, Langmuir : the ACS journal of surfaces and colloids.
[72] David E Williams,et al. Kinetics of immunoassays with particles as labels: effect of antibody coupling using dendrimers as linkers. , 2011, The Analyst.
[73] Birgit Samans,et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma , 2007, International journal of cancer.
[74] A. Davidoff,et al. In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. , 2007, Journal of pediatric surgery.